New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
07:41 EDTBAXS, SNN, RTIX, ANIK, OSIR, SMA, CNMD, GMED, BONE, NUVA, MDXG, AXGNCanaccord to hold a conference
Musculoskeletal Conference is being held in New Orleans, Louisiana on March 11.
News For GMED;ANIK;AXGN;CNMD;RTIX;MDXG;SMA;SNN;NUVA;OSIR;BAXS;BONE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 29, 2015
08:55 EDTNUVANuVasive settlement removes an overhang, says Wells Fargo
Wells Fargo believes the settlement NuVasive reached with the Department of Justice removes an overhang on the stock and that the $13.8M fine is "relatively immaterial." Wells notes NuVasive will likely not be subject to a corporate integrity agreement which it says would have increased expenses. It expects shares to move higher on the news and keeps an Outperform rating on the name.
08:20 EDTNUVANuVasive reaches agreement in principle to settle OIG matter
Subscribe for More Information
April 28, 2015
16:43 EDTANIKAnika announces Hyalofast abstracts, says 'positive clinical outcomes'
Anika Therapeutics announced that seven abstracts related to Hyalofast are scheduled for presentation at the 12th Annual World Congress of the International Cartilage Repair Society, May 8-11. "The research demonstrates that Anika’s HA-based scaffold, Hyalofast, enables patients to naturally regenerate cartilage. The research being presented on Hyalofast highlights the positive clinical outcomes of patients being treated in multiple areas, including the knees and ankles,” said Anika CEO Charles Sherwood. “The data validates the distinct advantages Hyalofast has over other products as the only HA-based scaffold for regeneration, as well as the safety and effectiveness of the procedure. We look forward to beginning a pivotal phase III clinical trial planned for Q4, and advancing Hyalofast toward commercialization in the United States," Sherwood added.
16:40 EDTANIKAnika Therapeutics targeting 5% Monovisc market share by end of FY15
Subscribe for More Information
16:39 EDTANIKAnika Therapeutics reports Q1 EPS 23c, two estimates 21c
Subscribe for More Information
07:39 EDTBONEBacterin receives coverage from MAC for hMatrix
Bacterin International Holdings announced that its Acellular Dermal Matrix allograft, hMatrix, has received coverage from Novitas Solutions, a Medicare Administrative Contractor, or "MAC". Novitas is one of eight MACs that are responsible for processing Medicare claims in one or more of twelve geographic areas, or "jurisdictions," in the United States. In addition to processing claims, each MAC is also responsible for issuing local coverage determinations that specify which health care products and services are reimbursable through the Medicare Fee-for-Service program in the regions under its jurisdiction.
April 27, 2015
19:52 EDTMDXGMiMedx sees FY15 revenue $180M-$190M, consensus $186.01M
Subscribe for More Information
19:52 EDTMDXGMiMedx sees Q2 revenue $44M-$46M, consenssu 43.91M
Sees Q2 operating profit in excess of 11%.
19:51 EDTMDXGMiMedx raises share repurchase program by $10M
Subscribe for More Information
19:49 EDTMDXGMiMedx reports Q1 EPS 4c, consensus 3c
Subscribe for More Information
08:10 EDTNUVANuVasive weakness creates buying opportunity, says RBC Capital
Subscribe for More Information
April 24, 2015
10:00 EDTCNMDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:13 EDTCNMDCONMED downgraded to Neutral from Buy at Ladenburg
Subscribe for More Information
April 23, 2015
17:00 EDTGMEDGlobus Medical appoints Daniel Scavilla as CFO
Subscribe for More Information
08:16 EDTRTIXRTI Surgical sees Q2 EPS 4c, consensus 4c
Subscribe for More Information
08:16 EDTRTIXRTI Surgical raises 2015 EPS outlook to 19c-23c from 17c-22c
Subscribe for More Information
08:14 EDTRTIXRTI Surgical reports Q1 EPS 5c, consensus 3c
Subscribe for More Information
April 22, 2015
16:19 EDTCNMDCONMED sees FY15 adjusted EPS $1.82-$1.92, consensus $1.86
The company reiterated its previously disclosed constant currency sales guidance, which calls for organic sales growth in 2015 to be in the range of 1%-3%. If foreign currency exchange rates hold near current levels, the company expects net sales for the last three quarters of 2015 to be negatively impacted by $3.9M as compared to prior sales guidance, which was based on January 23 currency rates. Using current exchange rates, CONMED now anticipates that reported sales for 2015 will be in the range of $723M-$738M, consensus $732.62M.
16:18 EDTCNMDCONMED reports Q1 adjusted EPS 42c, consensus 43c
Reports Q1 revenue $177.9M, consensus $174.98M.
10:17 EDTNUVAHigh option volume stocks
High option volume stocks: CAMP FTI NUVA ASHR MDRX AEC OIL TEL PODD SMCI
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use